Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.
Animals
Carcinoma, Pancreatic Ductal
/ immunology
Cell Line, Tumor
Female
Humans
Immunity, Innate
Immunotherapy, Adoptive
Macrophages
/ immunology
Male
Mice
Mice, Inbred C57BL
Neoplasm Transplantation
Pancreatic Neoplasms
/ immunology
Receptors, Antigen, T-Cell, alpha-beta
/ metabolism
T-Lymphocytes
/ immunology
Tumor Microenvironment
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
05
02
2019
revised:
14
05
2019
accepted:
27
06
2019
pubmed:
4
7
2019
medline:
4
8
2020
entrez:
4
7
2019
Statut:
ppublish
Résumé
Unconventional T-lymphocyte populations are emerging as important regulators of tumor immunity. Despite this, the role of TCRαβ
Identifiants
pubmed: 31266770
pii: 2159-8290.CD-19-0161
doi: 10.1158/2159-8290.CD-19-0161
pmc: PMC6726581
mid: NIHMS1533606
doi:
Substances chimiques
Receptors, Antigen, T-Cell, alpha-beta
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1288-1305Subventions
Organisme : NCI NIH HHS
ID : R01 CA168611
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA193111
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215471
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA186241
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK106025
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA069533
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
Microbiology. 2003 May;149(Pt 5):1095-102
pubmed: 12724371
Appl Environ Microbiol. 2003 May;69(5):2875-8
pubmed: 12732560
Cancer Res. 2003 Nov 15;63(22):8014-21
pubmed: 14633734
Genome Biol. 2006;7(10):R100
pubmed: 17076895
Cancer Cell. 2007 Mar;11(3):291-302
pubmed: 17349585
Cancer Immunol Immunother. 2009 May;58(5):709-18
pubmed: 18836718
Cancer Cell. 2009 Aug 4;16(2):91-102
pubmed: 19647220
Nat Immunol. 2010 Aug;11(8):701-8
pubmed: 20581831
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
PLoS One. 2011 Mar 21;6(3):e17996
pubmed: 21445311
J Mol Cell Biol. 2012 Feb;4(1):48-58
pubmed: 22294241
Gastroenterology. 2012 Oct;143(4):1061-72
pubmed: 22705178
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Exp Med. 2012 Aug 27;209(9):1671-87
pubmed: 22908323
J Immunol. 2013 May 1;190(9):4640-9
pubmed: 23536633
Nature. 2014 May 15;509(7500):361-5
pubmed: 24695216
Gastroenterology. 2014 Aug;147(2):473-84.e2
pubmed: 24801349
Cancer Cell. 2014 May 12;25(5):621-37
pubmed: 24823639
J Vis Exp. 2015 May 21;(99):e52836
pubmed: 26066790
Nature. 2016 Apr 14;532(7598):245-9
pubmed: 27049944
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Immunol Rev. 2016 Jul;272(1):120-38
pubmed: 27319347
Nat Commun. 2016 Jun 23;7:11653
pubmed: 27337592
Cell. 2016 Sep 8;166(6):1485-1499.e15
pubmed: 27569912
Front Immunol. 2017 Mar 10;8:237
pubmed: 28344578
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Nat Med. 2017 May;23(5):556-567
pubmed: 28394331
Immunology. 2017 Sep;152(1):36-51
pubmed: 28419443
J Exp Med. 2017 Jun 5;214(6):1711-1724
pubmed: 28442553
Cell Rep. 2017 Jul 18;20(3):558-571
pubmed: 28723561
Oncoimmunology. 2017 May 25;6(7):e1333210
pubmed: 28811976
Cancer Discov. 2018 Feb;8(2):196-215
pubmed: 29101162
Cancer Discov. 2018 Apr;8(4):403-416
pubmed: 29567829
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Trends Mol Med. 2018 May;24(5):472-489
pubmed: 29655673
Cancer Cell. 2018 Nov 12;34(5):757-774.e7
pubmed: 30423296
J Exp Med. 1997 Oct 20;186(8):1373-81
pubmed: 9334377